Innovent Biologics

View All

US/AZ deal; Alkermes’ Schizophrenia drug; Innovent/Lilly’s China market expansion; Rejection for Avenue

U.S., AstraZeneca strikes an antibody treatment USD 486 million deal The U.S. government awarded the pharma giant AstraZeneca a sum of USD 486 million for the development of up to 100,000 corona vaccine doses. The deal, under Operation Warp Speed, will people the manufacturing of antibody doses and facilitate th...

Find More

AbbVie & Genmab’s Collaboration; Lilly’s antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent;

AbbVie Seals a USD 750 M Bispecific Antibody Cancer Drug Deal with Genmab   AbbVie is set to reimburse Genmab USD 750 million upfront for a stake in a pipeline of anti-cancer bispecifics that is led by epcoritamab. The agreement features up to USD 3.2 billion in milestones, positions AbbVie to race Reg...

Find More

Wet Age-related macular degeneration treatment market
Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow down the progression of the vision loss but also kill the cause behind the degeneration of the macula. The present treatment approach requires intravitreal injection of anti-VE...

Find More

Innovent Biologics reaps; Jeff Aronin’s lead; Alexion gives out; Stoke Therapeutics receives

Innovent Biologics reaps USD 421 Million by Hong Kong IPO Innovent Biologics got delivered USD 421 million in its IPO. The Suzhou-based unicorn priced 236.35 million shares near the top of the range at HK USD 13.98. The USD 245 million is given by a group of 10 cornerstone investors, because of which Innovent’s tot...

Find More

transthyretin amyloidosis
Pandion bags $58M; Carmot Therapeutics grabs $15M; Innovent looks for IPO; Collaboration of Sandoz & Biocon

Pandion Therapeutics bags USD 58 million in series A Funding Focused on developing Targeted immune modulator drugs, Pandion Therapeutics has successfully grabbed USD 58 million in series A funding. The company is led by highly experienced professionals. Anthony Coyle (former senior vice president at Pfizer and globa...

Find More